Age, yr, mean ± SD | 52.3 ± 11.6 | 52.7 ± 11.4 | 0.7 |
Male sex | 240 (87.3) | 171 (87.2) | 0.99 |
Preoperative α-fetoprotein level ≥ 400 ng/mL | 86 (31.3) | 64 (32.6) | 0.8 |
Hepatitis B surface antigen positive | 241 (87.6) | 172 (87.8) | 0.97 |
Preoperative platelet count, ×109/L, mean ± SD | 193.2 ± 83.3 | 188.2 ± 67.6 | 0.5 |
Preoperative total bilirubin level, μmol/L, mean ± SD | 15.2 ± 6.7 | 15.8 ± 6.5 | 0.3 |
Preoperative albumin level, g/L, mean ± SD | 40.5 ± 3.8 | 40.8 ± 4.5 | 0.6 |
Preoperative alanine transaminase level ≥ 50 U/L | 70 (25.4) | 53 (27.0) | 0.7 |
Preoperative γ-glutamyl transpeptidase level ≥ 75 U/L | 101 (36.7) | 59 (30.1) | 0.1 |
Tumour size, cm, mean ± SD | 5.9 ± 3.7 | 6.2 ± 4.0 | 0.4 |
Multiple lesions | 29 (10.5) | 29 (14.8) | 0.2 |
Cirrhosis | 213 (77.4) | 113 (57.6) | < 0.001 |
Microvascular invasion | 105 (38.2) | 74 (37.8) | 0.9 |
Tumour differentiation | | | 0.97 |
Well | 32 (11.6) | 24 (12.2) | |
Moderate | 175 (63.6) | 125 (63.8) | |
Low | 68 (24.7) | 47 (24.0) | |
BCLC stage | | | 0.1 |
0 | 48 (17.4) | 21 (10.7) | |
A | 96 (34.9) | 69 (35.2) | |
B | 131 (47.6) | 106 (54.1) | |